A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial-Reference-Cited by-同舟云学术

A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial

Published:2010-06 Issue:1 Volume:103 Page:94-100
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Pinder S E, ,Duggan C,Ellis I O,Cuzick J,Forbes J F,Bishop H,Fentiman I S,George W D

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6605718.pdf

Reference30 articles.

1. Anderson TJ, Lamb J, Donnan P, Alexander FE, Huggins A, Muir BB, Kirkpatrick AE, Chetty U, Hepburn W, Smith A, Prescott RJ, Forrest P (1991) Comparative pathology of breast cancer in a randomised trial of screening. Br J Cancer 64: 108–113

2. Baxter NN, Virnig BA, Durham SB, Tuttle TM (2004) Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 17: 443–448

3. Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, Di Palma S, Simony-Lafontaine J, de Mascarel I, van de Vijver MJ (2001) Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organisation for Research and Treatment of Cancer Trial 10853. J Clin Oncol 19: 2263–2271

4. Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ, EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24: 3381–3387

5. Bobrow LG, Happerfield LC, Gregory WM, Spingall RD, Millis RR (1994) The classification of ductal carcinoma in situ and its association with biological markers. Semin Diagn Pathol 11: 199–207

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A prognostic and predictive computational pathology immune signature for ductal carcinoma in situ: retrospective results from a cohort within the UK/ANZ DCIS trial;The Lancet Digital Health;2024-08

2. Immune cell infiltrate in ductal carcinoma in situ and the risk of dying from breast cancer: case–control study;British Journal of Surgery;2024-01-31

3. Tumor microenvironment and immune system preservation in early-stage breast cancer: routes for early recurrence after mastectomy and treatment for lobular and ductal forms of disease;BMC Immunology;2024-01-25

4. Tumor microenvironment and immune system preservation in early-stage breast cancer: Routes for early recurrence after mastectomy and treatment for lobular and ductal forms of disease;2023-10-10

5. Can Molecular Biomarkers Help Reduce the Overtreatment of DCIS?;Current Oncology;2023-06-13